Subcutaneous and orthotopic pancreatic tumour models, and PDOs in the combination‐treated group were markedly smaller than those in the control or gemcitabine‐alone groups, which demonstrated that targeting ARPC1B+ CSCs by CK‐636 can sensitise pancreatic cancer to gemcitabine. Here, ARPC1B is linked to familial pancreatic carcinoma.